Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

(Reuters) - Bristol Myers Squibb posted better-than-expected third-quarter earnings on Thursday citing strong sales of ...

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...

See "Use of Non-GAAP Financial Information". All comparisons are made versus the same period in 2023 unless otherwise stated. Bristol Myers Squibb posted third quarter revenues of $11.9 billion, an ...

Investing.com -- Bristol-Myers Squibb (NYSE: BMY) raised its full-year earnings guidance as the company’s Q3 results handily ...

The drugmaker said it now expects revenue to rise 5% for the year, compared with prior guidance for gains at the upper-end of the single-digit percentage range. Earnings are now expected to hit 75 ...

A look at Kamala Harris and Donald Trump's stances on health care and what they've said about health care policy going into ...

Lawyers for AstraZeneca , Bristol Myers Squibb and Johnson & Johnson's Janssen on Wednesday urged a federal appeals court in ...

Part of the drugmakers' argument is that the federal scheme violates the First Amendment by compelling speech.

Operator instructions] I would now like to turn the conference over to your host, Joe Fletcher, senior vice president of ...

Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.